Scottish Medicines Consortium approves MabThera for vasculitis, Lyxumia for diabetes and Targaxan for liver disease
Drug regulator the Scottish Medicines Consortium (SMC) has today approved the National Health Service use of Swiss pharma major Roche’s (ROG: SIX) MabThera (rituximab) for patients suffering from potentially fatal forms of vasculitis.
The drug was given the green light as the first and only licensed treatment available for two potentially life-threatening auto-immune diseases – severe forms of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).
The two diseases affect more than 13,000 people in the UK and are characterized by the decaying of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze